The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Overview of the RESONATE-2 clinical trial of ibrutinib as front-line therapy
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of the Resonate-2 clinical trial of ibrutinib vs. chlorambucil as front-line therapy, in patients unfit for fludarabine, cyclophosphamide, rituximab (FCR) therapy. The Phase III results presented at the American Society of Hematology (ASH) 2015 Annual Meeting, show that 98% of patients in the ibrutinib arm have a progression free survival period longer than 2 years.
